الفهرس Only 14 pages are availabe for public view
 |  | from | 102 |  |  |
| | | from | 102 | | |
Abstract
Background: Lung cancer is the leading cause of cancer mortality worldwide, accounting for {u223C}1.3 million deaths each year, the majority are (NSCLC) account for 85%{u2013}90%. Previous studies found that patients who received two or more lines of systemic therapy had a lower risk of death than those who received BSC only. Objectives: This study analyzed the negative prognostic factors, common side effects and overall survival in patients who received second-line chemotherapy for advanced non-small cell lung cancer (NSCLC). Results: With univariate analysis, age (40-60) years (95% CI 1.287-23.759, p value 0.022) and stage IV disease (95% CI 1.205-11.063, p value 0.022) showed higher risk for mortality. By multivariate analysis stage IV found to have higher risk of mortality (3.752) than stage IIIb with (95% CI 0.969-14.535, p value 0.056).The Platinum + Taxanes arm added (3) months for the survival period, the median survival was (13 month Vs 10 months) with (p value of 0.4). The most common side effects was hematological seen in (93%) of patients followed by gastrointestinal in (78%). Conclusion: The results of our study showed that patients with advanced NSCLC have a higher risk of death mainly with stage IV disease and age between (40-60 years). Also we found that patients with a non squamous histology, good nutritional status and who have received platinum based as 1st line treatment followed by taxanes as 2nd line treatment could be expected to have a better prognosis and better outcome but was not significant